Characteristics | Pure RCC (n = 97) | RCC with sarcomatoid and/or rhabdoid differentiation (n = 28) | p |
---|---|---|---|
Age (years), median (IQR) | 60 (53–67) | 55 (52–63) | 0.205 |
Gender, n (%) | 0.614 | ||
Male | 68 (70.1) | 21 (75.0) | |
Female | 29 (29.9) | 7 (25.0) | |
Tumour side, n (%) | 0.510 | ||
Left | 25 (25.8) | 9 (32.1) | |
Right | 72 (74.2) | 19 (67.9) | |
Tumour size (cm), mean ± SD | 8.5 ± 3.2 | 10.4 ± 4.1 | 0.012 |
Thrombus level (Mayo), n (%) | 0.790 0.038 0.319 | ||
I | 29 (29.9) | 9 (32.1) | |
II | 40 (41.2) | 9 (32.1) | |
III | 19 (19.6) | 6 (21.4) | |
IV | 9 (9.3) | 4 (14.3) | |
Blood transfusion (cc), median (IQR) | 400 (0–2000) | 1600 (400–3200) | |
Tumour stage, n (%) | |||
T3b | 84 (86.6) | 21 (75.0) | |
T3c | 9 (9.3) | 4 (14.3) | |
T4 | 4 (4.1) | 3 (10.7) | |
Nodal status, n (%) | 1.000 | ||
N0/Nx | 88 (90.7) | 26 (92.9) | |
N+ | 9 (9.3) | 2 (7.1) | |
Metastatic status, n (%) | 0.060 | ||
M0 | 76 (78.4) | 17 (60.7) | |
M1 | 21 (21.6) | 11 (39.3) | |
Metastatic sites, n (%) | 0.701 | ||
Lung | 16 (64.0) | 8 (57.1) | |
Bone | 6 (24.0) | 5 (35.7) | |
Liver | 3 (12.0) | 1 (7.1) | |
Histologic subtype, n (%) | 0.454 | ||
Clear cell RCC | 77 (79.4) | 24 (85.7) | |
Non-clear cell RCC | 20 (20.6) | 4 (14.3) | |
Fuhrman grade, n (%) (n = 120) | 0.018 | ||
1–2 | 38 (40.4) | 4 (15.4) | |
3–4 | 56 (59.6) | 22 (84.6) | |
Tumour necrosis, n (%) | 0.015 | ||
Absent | 53 (54.6) | 8 (28.6) | |
Present | 44 (45.4) | 20 (71.4) | |
Adjuvant target therapy | 38(39.2) | 11(39.3) | 0.992 |